Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 4, 2016. The document serves as a notification of transactions involving directors or persons discharging managerial responsibilities, specifically regarding Ms. Emma Walmsley.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a specific executive compensation event and does not contain consolidated financial statements.
Material Changes
No material changes to the company's financial position or operations are reported in this document. The filing details a one-time cash payment to Ms. Walmsley following the vesting of 25% of an award made on May 1, 2010, under the GlaxoSmithKline Deferred Investment Award Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It strictly reports the transaction details: Ms. Walmsley received a cash payment of 1470.75 pence per ordinary share in respect of 14,784.871 notional ordinary shares.
Investor Verification Points
- Verify the total cash payout amount to Ms. Walmsley based on the share price and notional share count provided.
- Confirm the vesting schedule and terms of the GlaxoSmithKline Deferred Investment Award Plan referenced in the filing.
- Note that this filing does not reflect the company's broader financial performance for the period.